

May 15, 2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Outcome of the Board Meeting held on Friday, May 15, 2026

Dear Sir/Madam,

In furtherance to our intimation dated May 11, 2026, this is to inform you that pursuant to Regulations 30, 33, and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), the Board of Directors of the Company at its Meeting held today, i.e., May 15, 2026, has inter-alia:-

- (a) Considered and approved the Unaudited Financial Results for the quarter ended March 31, 2026, and Audited Financial Results of the Company for the financial year (‘FY’) ended March 31, 2026 (Standalone and Consolidated), along with the Auditor’s Report thereon.

A copy of the said results along with the Auditor’s Report issued by the Statutory Auditors of the Company is enclosed herewith as **Annexure – I**.

A declaration on auditor's report with unmodified opinion pursuant to the regulation 33(3)(d) of the SEBI Listing Regulations read with SEBI master circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (‘SEBI Master Circular’) is enclosed as ‘**Annexure – II**’.

- (b) Considered and approved Interim Dividend for the FY 2025- 26 at the rate of 10% per equity shares having face value of Rs. 10 (“Rupees Ten”) each as on the Record Date i.e, May 22, 2026. The dividend shall be paid on or before June 13, 2026 to those members, whose names appear on the Register of Members or in records of Depositories as beneficial owners as on the Record Date.

It is further informed that in terms of Regulation 42 of the Listing Regulations, the record date for determining the shareholders who shall be entitled to receive the interim dividend for FY 2025-26 is Friday, May 22, 2026.

- (c) Considered and approved Sub-division/ split of 1 (One) existing equity share of the Company having face value of Rs. 10/- (Rupees Ten only) each, fully paid-up, into 5 (Five) equity shares of the Company having face value of Rs. 2/- (Rupee Two only) each, fully paid-up.

In furtherance thereof, the Board of Directors has accorded its approval for the alteration of the Capital Clause of the Memorandum of Association of the Company so as to give effect to the aforesaid sub-division of equity shares, pursuant to which the altered Clause V shall stand substituted as follows:-

“The authorized share capital of the Company is Rs. 80,00,00,000/- (Rupees Eighty Crores only) divided into 40,00,00,000 (Forty Crore only) equity shares of Rs. 2 (Rupees Two only) each.”

The relevant details of sub-division of equity shares in terms of SEBI master circular are attached herewith as ‘**Annexure III**’.

- (d) Considered and approved Deletion/alteration/modification of Definition & Clauses in Articles of Association of the Company.

The relevant details in terms of SEBI master circular are attached herewith as ‘**Annexure IV**’.

- (e) Considered and approved appointment with change in designation of Dr. Ajay Thakker (DIN: 00120887) as a Chairman & Whole Time Director.

The relevant details in terms of SEBI master circular are attached herewith as ‘**Annexure V**’.

- (f) Approved appointment of Mr. Aditya Gupta, Senior Vice President – Corporate Affairs as senior managerial personnel of the company (“SMP”).

The relevant details in terms of SEBI master circular are attached herewith as ‘**Annexure VI**’.

- (g) Approved appointment of Dr. Tushar Patil, Head Operations, Dombivli as senior managerial personnel of the company (“SMP”).

The relevant details in terms of SEBI master circular are attached herewith as ‘**Annexure VII**’.

- (h) Approved appointment of Varma & Varma, as the Internal Auditor of the Company for the FY 2026-27.

The relevant details in terms of SEBI master circular are attached herewith as ‘**Annexure VIII**’.

- (i) Approved appointment of M/s V.J. Talati & Co. as the Cost Auditor of the Company for the FY 2026-27.

The relevant details in terms of SEBI master circular are attached herewith as ‘**Annexure IX**’.

The date of AGM and record date will be intimated separately.

The Board meeting commenced at 3:00 P.M. and was conclude at 5.50 P.M

The aforementioned information will be available at the website of the Company at www.jupiterhospital.com.

Thanking You,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary & Compliance Officer

KKC & Associates LLP
Chartered Accountants
 Sunshine Tower, Level 19
 Senapati Bapat Marg
 Elphinstone Road
 Mumbai-400 013
 Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
 405, Jay Commercial Plaza,
 Junction of S.L. Road & M.G. Road,
 Mulund (W),
 Mumbai- 400 080
 Telephone: 65525689

Independent Auditor's report on annual consolidated financial results of Jupiter Life Line Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
 The Board of Directors of
 Jupiter Life Line Hospitals Limited

Opinion

1. We have audited the accompanying consolidated financial results of Jupiter Life Line Hospitals Limited ('the Holding Company' or 'the Parent') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') for the year ended 31 March 2026, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate audited financial results of the subsidiaries, the aforesaid consolidated financial results:
 - 2.1. include the annual financial results of the following entities:

Sr. No.	Name of the Entity	Relationship
1	Jupiter Life Line Hospitals Limited	The Parent or the Holding Company
2	Jupiter Hospital Projects Private Limited ('JHPPL')	Subsidiary
3	Medulla Healthcare Private Limited	Subsidiary
4	Jupiter Hospital Pharmacy Private Limited	Subsidiary
4	Jupiter Pharmacy * (till conversion date)	Partnership Firm wherein the Parent holds 95%
5	Jupiter Gait Lab (dissolved on 30 June 2025)	Partnership Firm wherein the Parent holds 51%
6	Katyayini Hospitality	Partnership Firm wherein the Parent holds 95%
7	Mangleshwar Hospitality (dissolved on 1 August 2025)	Partnership Firm wherein JHPPL holds 95%
8	Vishesh Jupiter Pharmacy (dissolved on 1 August 2025)	Partnership Firm wherein JHPPL holds 95%

*converted to Jupiter hospital pharmacy private limited w.e.f. 01 May 2025

- 2.2. are presented in accordance with the requirements of the Listing Regulations in this regard; and
- 2.3. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS'), and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026.

Basis for opinion

3. We conducted our audit in accordance with the Standard on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in the 'Other Matters' paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the Consolidated Financial Results

4. These consolidated financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of these consolidated financial results that give a true and fair view of the consolidated net profit after tax and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Ind AS prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial result that give a true and fair view and are free from material misstatement, whether due to fraud or error, which has been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.
5. In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

7. Our objectives are to obtain reasonable assurance about whether the consolidated financial results are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- 8.1. Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - 8.2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
 - 8.3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - 8.4. Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - 8.5. Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
 - 8.6. Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated financial results. We are responsible for the direction, supervision, and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

9. We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
11. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

12. a) The consolidated financial results include financial results of 2 (two) subsidiaries whose Financial Results reflect total assets of Rs. 134.86 million as at 31 March 2026, total revenue of Rs. 101.29 million and Rs. 396.68 million, total net profit after tax of Rs. 14.46 million and Rs. 62.50 million for the quarter ended and for the year ended 31 March 2026 respectively, and cash Outflow(Net) of Rs. 0.54 million for the year ended 31 March 2026 as considered in the consolidated financial results. The financial statements of these entities have been audited by one of the joint auditors Aswin P. Malde & Co. The independent auditors' reports on financial results of these entities have been furnished to us and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
- b) The consolidated financial results include financial results of 1 (one) subsidiary whose Financial Results reflect total assets of Rs. 3,344.27 million as at 31 March 2026, total revenue of Rs. 1,227.88 million and Rs. 2,499.08 million, total net loss after tax of Rs.7.43 million and Rs. 33.68 million for the quarter ended and for the year ended 31 March 2026 respectively, and cash Inflow(Net) of Rs. 87.52 million for the year ended 31 March 2026 as considered in the consolidated financial results. The financial statements of these entities have been audited by their independent auditor. The independent auditors' reports on financial results of this entity have been furnished to us and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this entity, is based solely on the report of such auditor and the procedures performed by us are as stated in paragraph above.
13. The consolidated financial results include financial results of 1 (one) partnership firm, whose Financial Results reflect of total asset of Rs. 18.50 million as at 31 March 2026, total revenue of Rs. 32.71 million and Rs. 129.77 million, total net loss after tax of Rs. 1.61 million and Rs. 2.76 million for the quarter and for the year ended 31 March 2026, and net cash flow of Rs. 6.53 million for the year ended 31 March 2026 as considered in the consolidated financial results. These unaudited financial results have been furnished to us by the Board of Directors and our opinion on the consolidated financial results, in so



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

far as it relates to the amounts and disclosures included in respect of these partnership firms is based solely on such unaudited financial results. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial results are not material to the Group.

14. Our opinion on the consolidated financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results certified by the Board of Directors.
15. Attention is drawn to the fact that the consolidated financial results of the Company for the corresponding quarter and year ended 31 March 2025 were audited by one of the joint auditor Aswin P. Malde & Co whose report dated 09 May 2025 expressed an unmodified opinion on the consolidated financial results. Our opinion is not modified in respect of this matter.
16. The consolidated financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For KKC & Associates LLP
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621

Hasmukh
Bhavanji
Dedhia

Digitally signed by
Hasmukh Bhavanji
Dedhia
Date: 2026.05.15
17:35:24 +05'30'



Hasmukh B Dedhia
Partner
ICAI Membership No: 33494
UDIN: 26033494QYGMMR8710
Place: Mumbai
Date: 15 May 2026

For Aswin P. Malde & Co.
Chartered Accountants

Firm Registration Number: 100725W

Aswin
Popatal
Malde

Digitally signed by
Aswin Popatal
Malde
Date: 2026.05.15
17:44:51 +05'30'



Aswin P. Malde
Proprietor
ICAI Membership No: 032662
UDIN: 26032662TOCJLX5857
Place: Mumbai
Date: 15 May 2026

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in Million)

Sl. No	Particulars	Quarter Ended			Year Ended	
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		(Refer Note 5)	Unaudited	(Refer Note 5)	Audited	Audited (Refer Note 8)
1.	Income					
a.	Revenue from operations	3,878.38	3,653.67	3,366.61	14,997.87	13,024.02
b.	Other income	91.49	91.29	68.83	423.68	283.47
	Total Income	3,969.87	3,744.96	3,435.44	15,421.55	13,307.49
2.	Expenses					
a.	Purchases of medical consumables, drugs and surgical items	768.49	767.08	656.35	2,991.43	2,581.70
b.	Changes in inventories of medical consumables, drugs and surgical items	(31.08)	(76.64)	17.70	(118.75)	(26.88)
c.	Employee benefit expense	677.17	636.46	574.08	2,563.25	2,252.36
d.	Professional fees	915.96	867.17	793.21	3,640.29	3,052.82
e.	Finance costs	90.08	75.48	56.10	326.63	107.06
f.	Depreciation and amortisation expenses	232.57	217.03	176.52	876.40	570.83
g.	Other expenses	656.21	625.32	528.25	2,489.07	2,162.84
	Total Expenses	3,309.40	3,111.90	2,802.21	12,768.32	10,700.73
3.	Profit before exceptional items and tax (1-2)	660.47	633.06	633.23	2,653.23	2,606.76
4.	Exceptional (loss)/ gain	15.09	(63.96)	-	(48.87)	-
5.	Profit before tax (3-4)	675.56	569.10	633.23	2,604.36	2,606.76
6.	Tax expenses					
a.	Current tax	103.94	154.53	147.43	644.91	630.79
b.	Short/ (Excess) Provision of earlier years	(7.48)	0.06	0.76	(7.42)	0.76
c.	Deferred tax charge/ (credit)	76.43	(10.47)	32.22	25.00	37.67
	Total tax expense	172.89	144.12	180.41	662.49	669.22
7.	Net Profit for the period / year (5-6)	502.67	424.98	452.82	1,941.87	1,937.54
8.	Other Comprehensive income					
	Items that will not be reclassified to profit or loss					
	(i) Remeasurement of the defined benefit liabilities/ (assets)	5.20	-	(15.69)	5.20	(15.69)
	(ii) Deferred tax relating to items that will not be reclassified to Profit or Loss	(1.18)	-	3.94	(1.18)	3.94
	Total other comprehensive income/ (loss)	4.02	-	(11.75)	4.02	(11.75)
	Total comprehensive income for the period/ year	506.69	424.98	441.07	1,945.89	1,925.79
	Profit/(Loss) attributable to:					
	i. Owners of the Company	506.15	425.54	440.04	1,944.08	1,920.25
	ii. Non-Controlling Interests	0.54	(0.56)	1.03	1.81	5.54
	Other Comprehensive income attributable to:					
	i. Owners of the Company	3.93	-	(11.75)	3.93	(11.75)
	ii. Non-Controlling Interests	0.09	-	-	0.09	-
	Total Comprehensive income attributable to:					
	i. Owners of the Company	506.06	425.54	440.04	1,943.99	1,920.25
	ii. Non-Controlling Interests	0.63	(0.56)	1.03	1.90	5.54
	Paid up Equity Share Capital (Face value ₹ 10 per share)	655.66	655.66	655.66	655.66	655.66
	Other Equity				14,785.18	12,906.76
	Earnings per equity share					
	Basic (in ₹)	7.66	6.49	6.89	29.59	29.47
	Diluted (in ₹)	7.66	6.49	6.89	29.59	29.47
		(Not annualised)	(Not annualised)	(Not annualised)		

ANKIT AJAY THAKKER
Credentialed by ANKIT AJAY THAKKER Date: 2024.06.15 17:41:30 -402397



JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

NOTES TO THE STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

1. The above consolidated financial results of Jupiter Life Line Hospitals Limited ('the Company') and its subsidiaries (together referred to as "the Group") for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 15, 2026. These results have been subjected to audit by the joint statutory auditors of the Company, who have issued an unmodified report.
2. These consolidated financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS), as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015, the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other accounting principles generally accepted in India.
3. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed the financial implications of the changes arising from the implementation of the New Labour Codes in accordance with the guidance issued by the Institute of Chartered Accountants of India and based on actuarial valuation which has resulted in increase in gratuity liability arising out of past service cost by Rs. 48.87 Million (net of subsequent reversal upon actualisation of charge). Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount under "Exceptional Items" in the consolidated financial results for the quarter and year ended March 31, 2026.
4. The Group is primarily engaged in the business of Healthcare services in India, which constitutes its only reportable business and geographical segment in accordance with Ind AS 108 - Operating Segments. Accordingly, no separate segment disclosures are required. Further, segment reporting for its Hotel division is not required, as its contribution to the Group's total revenue, profit, and assets is below the 10% thresholds specified under Ind AS 108.
5. The figures for quarter ended March 31, 2026 and for the corresponding quarter ended March 31, 2025 are arrived at as the difference between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
6. The Board of Directors of the Holding Company at their meeting held on May 15, 2026 declared an interim dividend of Rs. 1 per share for the financial year 2025-26. The record date for the same is May 22, 2026.
7. The proposed merger of Medulla Healthcare Private Limited ("Transferor Company"), a direct wholly-owned subsidiary of Jupiter Life Line Hospitals Limited ("Transferee Company") with the Transferee Company with effect from April 1, 2025 is pending for final sanction of the Honourable National Company Law Tribunal, Mumbai. Thus, effect of the proposed scheme is not given in the current financial statements (being not material) of the Transferee Company.
8. In case of non-body corporates (partnership firms), consolidation is done considering these entities as subsidiaries and consequently the numbers for previous quarters, period and year are accordingly restated.
9. Previous period figures have been regrouped and/or reclassified to conform to the current year presentation, wherever necessary.
10. The consolidated financial results are available on the Company's website (www.jupiterhospital.com) and on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com).



For Jupiter Life Line Hospitals Limited

ANKIT AJAY THAKKER
Digitally signed by
ANKIT AJAY THAKKER
Date: 2026.05.15
17:03:45 +05'30'

Dr. Ankit Thakker
Managing Director and CEO
DIN: 02874715

Place: Mumbai
Date: May 15, 2026

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai,

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 **Email:** info@jupiterhospital.com **Web:** www.jupiterhospital.com

AUDITED CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2026

(₹ In Million)

Particulars	As at March 31, 2026	As at March 31, 2025
ASSETS		
(a) Property, plant and equipment	12,768.59	8,994.19
(b) Right of use assets	990.61	740.26
(c) Capital work-in-progress	1,292.12	1,851.10
(d) Other intangible assets	79.56	45.53
(e) Financial assets		
(i) Investments	1.00	1.23
(ii) Other financial assets	332.50	535.21
(f) Deferred tax assets (net)	198.34	186.33
(g) Other non-current assets	1,319.57	78.28
TOTAL NON-CURRENT ASSETS	16,982.29	12,432.13
CURRENT ASSETS		
(a) Inventories	383.36	264.61
(b) Financial assets		
(i) Investments	4,857.04	5,070.98
(ii) Trade receivables	755.39	432.33
(iii) Cash and cash equivalents	547.61	925.16
(iv) Bank balances other than (iii) above	34.07	24.66
(v) Other financial assets	64.59	27.00
(c) Current tax assets (net)	64.95	61.93
(d) Other current assets	141.99	118.70
TOTAL CURRENT ASSETS	6,849.00	6,925.37
TOTAL ASSETS	23,831.29	19,357.50
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	655.66	655.66
(b) Other equity	14,785.18	12,906.76
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY	15,440.84	13,562.42
(c) Non-Controlling interest	0.09	0.62
TOTAL EQUITY	15,440.93	13,563.04
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	5,008.97	3,217.45
(ii) Lease liabilities	655.33	623.41
(b) Provisions	164.61	112.21
(c) Deferred tax liabilities (net)	295.70	257.51
TOTAL NON-CURRENT LIABILITIES	6,124.61	4,210.58
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	76.30	39.68
(ii) Lease liabilities	101.80	50.91
(iii) Trade payables		
(A) Dues to micro and small enterprises	303.75	105.48
(B) Dues to other than micro and small enterprises	651.64	585.50
(iv) Other financial Liabilities	709.33	513.14
(b) Other current liabilities	296.80	234.02
(c) Provisions	92.01	20.23
(d) Current tax liabilities (net)	34.12	34.92
TOTAL CURRENT LIABILITIES	2,265.75	1,583.88
TOTAL LIABILITIES	8,390.36	5,794.46
TOTAL EQUITY AND LIABILITIES	23,831.29	19,357.50



ANKIT AJAY THAKKER Digitally signed by ANKIT AJAY THAKKER Date: 2026.03.19 17:04:10 +05'30'

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026

(**₹ In Million**)

Particulars	Year ended	
	March 31, 2026	March 31, 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Taxation and Exceptional Items	2,653.23	2,606.76
Adjustments for:		
Share of Profit in partnership firms	0.01	0.08
Depreciation and amortisation expenses	876.40	570.83
Finance costs	326.62	107.06
Interest income	(291.68)	(197.54)
Interest income on income tax refund	(2.68)	-
Provision for employee benefits	59.21	28.08
(Profit)/loss on sale/scrap/written off of property, plant and equipment (net)	1.67	29.16
Dividend income	(0.08)	(0.08)
Rent received	(0.48)	-
Net loss/(gain) on sale of investments	(131.46)	(44.64)
Net loss/(gain) arising on fair valuation of investments	18.57	(18.57)
Bad Debts written off	10.49	-
Allowance and Provision for doubtful debts	9.49	18.16
Balance written off/back and other non cash item/exceptional items	0.40	-
Lease Expenses	0.28	-
	876.76	492.54
Operating Profit before Working Capital changes	3,529.99	3,099.30
Movements in Working Capital:		
(Increase)/ Decrease in Operating Assets		
Trade receivables	(343.98)	124.00
Inventories	(118.75)	(26.89)
Loans and other financial assets	(0.83)	39.05
Other assets	(64.97)	(59.44)
(Decrease)/ Increase in Operating Liabilities		
Trade payables	268.27	133.19
Other financial liabilities	64.82	3.66
Other liabilities and provisions	(18.83)	(3.47)
	(214.27)	210.10
Cash generated from Operations	3,315.72	3,309.40
Income taxes paid/refund (net)	(638.64)	(642.01)
Net Cash generated from Operating Activities	2,677.08	2,667.39
B. CASH FLOW FROM INVESTING ACTIVITIES		
Payment to acquire property, plant and equipment, CWIP and intangible assets	(5,018.45)	(3,275.87)
Proceeds from sale of property, plant and equipment	2.71	4.03
(Increase)/decrease in deposits	(9.41)	1,782.75
Interest received	235.33	195.83
Dividend received	0.08	0.08
Rent received	0.48	-
Investment in subsidiaries and partnership firms	58.62	31.10
Purchase of current Investments	(8,207.63)	(6,261.23)
Proceeds from sale of current Investments	8,518.95	2,550.00
Net Cash generated from/ (used in) Investing Activities	(4,419.32)	(4,973.31)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from secured borrowings	1,860.43	3,257.13
Repayment of secured borrowings	(32.55)	-
Payment of lease liabilities	(162.18)	(109.39)
Finance cost paid	(235.44)	(77.41)
Dividend paid	(65.57)	(65.57)
Distribution of profit to Non-controlling interests	-	(37.71)
Net Cash (used in)/ generated by Financing Activities	1,364.69	2,967.05
Net increase in Cash and Cash Equivalents (A+B+C)	(377.55)	661.13
Cash and Cash Equivalents at the beginning of the year	925.16	264.03
Cash and Cash Equivalents at the end of year	547.61	925.16

1 The above Consolidated Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - "Statement of Cash Flows".

2 Cash and cash equivalents comprise of:

Particulars	March 31, 2026	March 31, 2025
Balances with Bank		
In Current account	535.04	159.70
Fixed deposits with bank - maturity less than 3 months	-	753.75
Cash on hand	12.57	11.71
Total	547.61	925.16

ANKIT AJAY Dignity & growth by
THAKKER 2007, LAY TOWER
Date: 2026.03.15
172646-0299



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

Independent Auditor's report on annual standalone financial results of Jupiter Life Line Hospitals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Jupiter Life Line Hospitals Limited

Opinion

1. We have audited the accompanying standalone financial results of Jupiter Life Line Hospitals Limited ('the Company') for the year ended 31 March 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial results:
 - 2.1. are presented in accordance with the requirements of the Listing Regulations in this regard; and
 - 2.2. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards ('Ind AS') and other accounting principles generally accepted in India, of the net profit and Other Comprehensive Income and Other Financial Information for the year ended 31 March 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standard on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013 ('the Act'). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the Standalone Financial Results

4. These standalone financial results have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors is responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit after tax and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS prescribed under Section 133 of the Act read with relevant



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

rules issued thereunder and other accounting principles generally accepted in India and in compliance with the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which has been used for the purpose of preparation of the standalone financial results by the Directors of the Company, as aforesaid.

5. In preparing the standalone financial results, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

7. Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - 8.1. Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - 8.2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

reference to standalone financial statements in place and the operating effectiveness of such controls.

- 8.3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- 8.4. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- 8.5. Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the standalone financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

11. Attention is drawn to the fact that the audited standalone financial results of the Company for the corresponding quarter and year ended 31 March 2025 were audited by one of the joint auditor Aswin P. Malde & Co whose report dated 9 May 2025, expressed an unmodified opinion on those audited standalone financial results.
12. The standalone financial results reflect the Company's share of net loss after tax of Rs. 1.99 million and Rs. 2.62 million for the quarter ended and for the year ended 31 March 2026 respectively, in respect of 1 (one) partnership firm. These financial results have been furnished to us by the Board of Directors and our opinion on the standalone financial results, in so far as it relates to the amounts and disclosures included in respect of these partnership firms is based solely on such unaudited financial results. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial results are not material to the Company.



KKC & Associates LLP
Chartered Accountants
Sunshine Tower, Level 19
Senapati Bapat Marg
Elphinstone Road
Mumbai-400 013
Telephone: +91 22 6143 7333

Aswin P. Malde & Co.
Chartered Accountants
405, Jay Commercial Plaza,
Junction of S.L. Road & M.G. Road,
Mulund (W),
Mumbai- 400 080
Telephone: 65525689

13. Our opinion on the standalone financial results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results/financial information certified by the Board of Directors.
14. The standalone financial results include the result for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **KKC & Associates LLP**
Chartered Accountants
(formerly Khimji Kunverji & Co LLP)
Firm Registration Number: 105146W/W100621

Hasmukh
Bhavanji
Dedhia

Digitally signed by
Hasmukh Bhavanji
Dedhia
Date: 2026.05.15
17:34:21 +05'30'



Hasmukh B Dedhia
Partner
ICAI Membership No: 33494
UDIN: 26033494HASGON9001
Place: Mumbai
Date: 15 May 2026

For **Aswin P. Malde & Co.**
Chartered Accountants

Firm Registration Number: 100725W

Aswin
Popatlal
Malde

Digitally signed by
Aswin Popatlal Malde
Date: 2026.05.15
17:46:19 +05'30'



Aswin P. Malde
Proprietor
ICAI Membership No: 032662
UDIN: 26032662SXPPTC6829
Place: Mumbai
Date: 15 May 2026

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ In Million)

Sl. No.	Particulars	Quarter Ended			Year Ended	
		March 31, 2026	December 31, 2025	March 31, 2025	March 31, 2026	March 31, 2025
		(Refer Note 5)	Unaudited	(Refer Note 5)	Audited	Audited
1.	Income					
a.	Revenue from operations	3,124.23	2,913.98	2,737.71	11,976.24	10,600.65
b.	Other income	89.46	91.60	70.94	422.51	280.71
	Total Income	3,213.69	3,005.58	2,808.65	12,398.75	10,881.36
2.	Expenses					
a.	Purchases of medical consumables, drugs and surgical items	597.19	568.32	501.83	2,236.18	1,925.91
b.	Changes in inventories of medical consumables, drugs and surgical items	(42.13)	(52.29)	15.41	(103.40)	(14.08)
c.	Employee benefit expense	517.39	482.71	449.19	1,958.53	1,772.23
d.	Professional fees	725.94	661.36	629.18	2,864.99	2,461.49
e.	Finance costs	42.23	26.48	40.02	128.35	86.05
f.	Depreciation and amortisation expense	184.68	168.19	133.77	686.31	424.08
g.	Other expenses	544.50	497.76	421.44	2,018.54	1,762.24
	Total Expenses	2,569.80	2,352.53	2,190.84	9,789.50	8,417.92
3.	Profit before exceptional items and tax (1-2)	643.89	653.05	617.81	2,609.25	2,463.44
4.	Exceptional (loss)/ gain	11.55	(55.44)	-	(43.89)	-
5.	Profit before tax (3-4)	655.44	597.61	617.81	2,565.36	2,463.44
6.	Tax expenses					
a.	Current tax	98.11	148.87	139.99	621.44	604.33
b.	Short/ (Excess) Provision of earlier years	(7.42)	-	-	(7.42)	-
c.	Deferred tax charge/ (credit)	72.71	5.95	33.35	37.54	12.09
	Total tax expense	163.40	154.82	173.34	651.56	616.42
7.	Net Profit for the period/ year (5-6)	492.04	442.79	444.47	1,913.80	1,847.02
8.	Other Comprehensive income					
	Items that will not be reclassified to profit or loss					
	(i) Remeasurement of the defined benefit liabilities/ (assets)	2.57	-	(11.46)	2.57	(11.46)
	(ii) Deferred tax relating to items that will not be reclassified to Profit or Loss	(0.65)	-	2.88	(0.65)	2.88
	Total other comprehensive income/ (loss)	1.92	-	(8.58)	1.92	(8.58)
	Total comprehensive income for the period/ year	493.96	442.79	435.89	1,915.72	1,838.44
	Paid up Equity Share Capital (Face value ₹ 10 per share)	655.66	655.66	655.66	655.66	655.66
	Other Equity				15,419.91	13,569.76
	Earnings per equity share					
	Basic (in ₹)	7.51	6.75	6.78	29.19	28.17
	Diluted (in ₹)	7.51	6.75	6.78	29.19	28.17
		(Not annualised)	(Not annualised)	(Not annualised)		

ANKIT AJAY Digitally signed by
THAKKER
Date: 2026.06.13
17:09:12 +05'30'



JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 Email: info@jupiterhospital.com Web: www.jupiterhospital.com

NOTES TO THE AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

1. The above standalone financial results of Jupiter Life Line Hospitals Limited ('the Company') for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 15, 2026. These results have been subjected to audit by the joint statutory auditors of the Company, who have issued an unmodified report.
2. These standalone financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS), as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015, the relevant rules issued thereunder, and in compliance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other accounting principles generally accepted in India.
3. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws ('New Labour Codes'). The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed the financial implications of the changes arising from the implementation of the New Labour Codes in accordance with the guidance issued by the Institute of Chartered Accountants of India and based on actuarial valuation which has resulted in increase in the gratuity liability arising out of past service cost by Rs. 43.89 Millions (net of subsequent reversal upon actualisation of charge). Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Company has presented this incremental amount under "Exceptional Items" in the standalone financial results for the quarter and year ended March 31, 2026.
4. The Company is primarily engaged in the business of Healthcare services in India, which constitutes its only reportable business and geographical segment in accordance with Ind AS 108 - Operating Segments. Accordingly, no separate segment disclosures are required. Further, segment reporting for its Hotel division is not required, as its contribution to the Company's total revenue, profit, and assets is below the 10% thresholds specified under Ind AS 108.
5. The figures for quarter ended March 31, 2026 and for the corresponding quarter ended March 31, 2025 are arrived at as the difference between audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
6. The Board of Directors at their meeting held on May 15, 2026 declared an interim dividend of Rs. 1 per share for the financial year 2025-26. The record date for the same is May 22, 2026.
7. The proposed merger of Medulla Healthcare Private Limited ("Transferor Company"), a direct wholly-owned subsidiary of Jupiter Life Line Hospitals Limited ("Transferee Company") with the Transferee Company with effect from April 1, 2025 is pending for final sanction of the Honourable National Company Law Tribunal, Mumbai. Thus, effect of the proposed scheme (being not material) is not given in the current financial statements of the Transferee Company.
8. Previous period figures have been regrouped and/or reclassified to conform to the current period presentation, wherever necessary.
9. The financial results are available on the Company's website (www.jupiterhospital.com) and on the websites of the Stock Exchanges (www.bseindia.com and www.nseindia.com).



For Jupiter Life Line Hospitals Limited

Digitally signed by
ANKIT AJAY THAKKER
Date: 2026.05.15
17:09:41 +0530'

Dr. Ankit Thakker
Managing Director and CEO
DIN: 02874715

Place: Mumbai

Date: May 15, 2026

JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 **Email:** info@jupiterhospital.com **Web:** www.jupiterhospital.com


AUDITED STANDALONE BALANCE SHEET AS AT MARCH 31, 2026

(₹ In Million)

Particulars	As at March 31, 2026	As at March 31, 2025
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	10,175.20	6,348.42
(b) Right of use assets	974.60	740.26
(c) Capital work-in-progress	1,127.05	1,625.62
(d) Other intangible assets	78.03	43.32
(e) Financial assets		
(i) Investments	940.30	940.34
(iii) Other financial assets	324.80	527.70
(f) Other non-current assets	1,263.55	77.63
TOTAL NON-CURRENT ASSETS	14,883.53	10,303.29
CURRENT ASSETS		
(a) Inventories	285.13	181.73
(b) Financial assets		
(i) Investments	4,863.69	5,122.59
(ii) Trade receivables	671.39	377.76
(iii) Cash and cash equivalents	374.33	845.39
(iv) Bank balances other than (iii) above	33.95	24.54
(v) Loans	322.21	202.47
(vi) Other financial assets	64.59	28.26
(c) Other current assets	103.94	89.92
TOTAL CURRENT ASSETS	6,719.23	6,872.66
TOTAL ASSETS	21,602.76	17,175.95
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity share capital	655.66	655.66
(b) Other equity	15,419.91	13,569.76
TOTAL EQUITY	16,075.57	14,225.42
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	2,584.12	742.50
(ii) Lease liabilities	644.79	623.41
(b) Provisions	152.24	105.42
(c) Deferred tax liabilities (net)	295.70	257.51
TOTAL NON-CURRENT LIABILITIES	3,676.85	1,728.84
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	26.20	7.50
(ii) Lease liabilities	96.04	50.91
(iii) Trade payables		
(A) Dues to micro and small enterprises	254.52	94.09
(B) Dues to other than micro and small enterprises	472.02	447.66
(iv) Other financial Liabilities	649.21	358.58
(b) Other current liabilities	258.38	198.36
(c) Provisions	62.88	56.14
(d) Current tax liabilities (net)	31.09	8.45
TOTAL CURRENT LIABILITIES	1,850.34	1,221.69
TOTAL LIABILITIES	5,527.19	2,950.53
TOTAL EQUITY AND LIABILITIES	21,602.76	17,175.95

ANKIT
AJAY
THAKKER

Digitally signed
by ANKIT AJAY
THAKKER
Date: 2026.05.15
17:09:59 +05'30'



JUPITER LIFE LINE HOSPITALS LIMITED

CIN: L85100MH2002PLC137908

Registered Office: 1004, 10th floor, '360 Degree Business Park', Maharana Pratap Chowk, LBS Marg, Mulund (W), Mumbai, Maharashtra - 400 080

Corporate Office: Eastern Express Highway, Thane (W), Maharashtra - 400 601

Telephone No: 022 62976630 **Email:** info@jupiterhospital.com **Web:** www.jupiterhospital.com

AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026

(₹ In Million)

Particulars	Year Ended	
	March 31, 2026	March 31, 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before Taxation and Exceptional Items	2,609.25	2,463.44
Adjustments for:		
Share of Profit in partnership firms	2.62	(47.16)
Depreciation and amortisation expense	686.31	424.08
Finance costs	128.35	86.05
Interest income	(291.35)	(195.83)
Provision for employee benefits	31.85	21.44
(Profit)/loss on sale/scrap/written off of property, plant and equipment (net)	1.30	25.77
Dividend income	(0.08)	(0.08)
Net loss/(gain) on sale of investments	(131.46)	(44.64)
Net loss/(gain) arising on fair valuation of investments	18.57	(18.57)
Bad Debts written off	3.87	-
Allowance and Provision for doubtful debts	14.64	10.17
	464.62	261.23
Operating Profit before Working Capital changes	3,073.87	2,724.67
Movements in Working Capital:		
(Increase)/ Decrease in Operating Assets		
Trade receivables	(312.14)	75.50
Inventories	(103.40)	(14.09)
Loans and other financial assets	(0.71)	38.17
Other assets	(34.23)	(25.85)
(Decrease)/ Increase in Operating Liabilities		
Trade payables	184.79	50.38
Other financial liabilities	51.30	-
Other liabilities and provisions	40.41	(38.43)
	(173.98)	85.68
Cash generated from Operations	2,899.89	2,810.35
Income taxes paid/refund (net)	(591.38)	(623.88)
Net Cash generated from Operating Activities	2,308.51	2,186.47
B. CASH FLOW FROM INVESTING ACTIVITIES		
Payment to acquire property, plant and equipment, CWIP and intangible assets	(4,831.89)	(2,804.12)
Proceeds from sale of property, plant and equipment	2.71	0.71
(Increase)/decrease in deposits	(9.41)	1,738.29
Interest received	235.33	195.83
Dividend received	0.08	0.08
Investment in subsidiaries and partnership firms	59.03	31.18
Purchase of current Investments	(8,208.81)	(6,261.23)
Proceeds from sale of current Investments	8,518.95	2,550.00
Net Cash generated from/ (used in) Investing Activities	(4,234.01)	(4,549.26)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from secured borrowings	1,867.82	750
Repayment of secured borrowings (net)	(7.50)	-
Loan (given) /repaid by Subsidiary	(119.74)	2,499.74
Payment of lease liabilities	(172.10)	(109.39)
Finance cost paid	(48.47)	(56.40)
Dividend paid	(65.57)	(65.57)
Net Cash (used in)/ generated by Financing Activities	1,454.44	3,018.38
Net increase in Cash and Cash Equivalents (A+B+C)	(471.06)	655.59
Cash and Cash Equivalents at the beginning of the year	845.39	189.80
Cash and Cash Equivalents at the end of year	374.33	845.39

1 The above Standalone Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - "Statement of Cash Flows".

2 Cash and cash equivalents comprise of:

Particulars	March 31, 2026	March 31, 2025
Balances with Bank		
In Current account	365.32	85.72
Fixed deposits with bank - maturity less than 3 months	-	753.75
Cash on hand	9.01	5.92
Total	374.33	845.39



Annexure – II

May 15, 2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Declaration pursuant to Regulation 33(3)(d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')


Dear Sir/ Madam,

In compliance with Regulation 33(3)(d) of Listing Regulations and SEBI master circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, we hereby declare that, Statutory Auditors of our Company M/s. Aswin P. Malde, Chartered Accountants (FRN: 100725W) & KKC & Associates LLP Chartered Accountants (FRN: 105146W/W-100621) have issued an Audit Report with unmodified opinion on Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking you.

For JUPITER LIFE LINE HOSPITALS LIMITED



Sivasis Sen
Chief Financial Officer

Annexure – III

Sr No	Particulars	Remarks																											
1.	Split Ratio	Sub-division/Split of 1 (One) existing equity share of the Company having face value of Rs. 10/- (Rupees Ten only) each, fully paid-up, into 5 (Five) equity shares of the Company having face value of Rs. 2/- (Rupee Two only) each, fully paid-up.																											
2.	Rationale behind the Split	To make the Company's equity shares more affordable and enhance their liquidity for increased market participation by investors, especially retail / individual investors.																											
3.	Pre and Post Share Capital – Authorized, Paid-up, and subscribed	<table border="1"> <thead> <tr> <th rowspan="2">Types of Capital</th> <th colspan="3">Pre-sub-division/split</th> <th colspan="3">Post sub-division/split</th> </tr> <tr> <th>No. of equity share</th> <th>Face Value (Rs)</th> <th>Total equity share capital (Rs)</th> <th>No. of equity shares</th> <th>Face Value (Rs)</th> <th>Total equity share capital (Rs)</th> </tr> </thead> <tbody> <tr> <td>Authorized Equity Share Capital</td> <td>8,00,00,000</td> <td>10</td> <td>80,00,00,000</td> <td>40,00,00,000</td> <td>2</td> <td>80,00,00,000</td> </tr> <tr> <td>Issued, Subscribed and Paid-up Equity Share Capital</td> <td>6,55,66,022</td> <td>10</td> <td>65,56,60,220</td> <td>32,78,30,110</td> <td>2</td> <td>65,56,60,220</td> </tr> </tbody> </table>	Types of Capital	Pre-sub-division/split			Post sub-division/split			No. of equity share	Face Value (Rs)	Total equity share capital (Rs)	No. of equity shares	Face Value (Rs)	Total equity share capital (Rs)	Authorized Equity Share Capital	8,00,00,000	10	80,00,00,000	40,00,00,000	2	80,00,00,000	Issued, Subscribed and Paid-up Equity Share Capital	6,55,66,022	10	65,56,60,220	32,78,30,110	2	65,56,60,220
		Types of Capital		Pre-sub-division/split			Post sub-division/split																						
			No. of equity share	Face Value (Rs)	Total equity share capital (Rs)	No. of equity shares	Face Value (Rs)	Total equity share capital (Rs)																					
		Authorized Equity Share Capital	8,00,00,000	10	80,00,00,000	40,00,00,000	2	80,00,00,000																					
Issued, Subscribed and Paid-up Equity Share Capital	6,55,66,022	10	65,56,60,220	32,78,30,110	2	65,56,60,220																							
<i>Note :- The sub-division/split of Equity Shares of the Company is subject to the approval of shareholders</i>																													
4.	Expected time of completion	Tentatively within one month from receipt of all the regulatory/statutory approvals and the members' approval.																											
5.	Class of Shares which are subdivided	Equity shares having face value of Rs. 10/- (Rupees Ten only) each, fully paid-up																											
6.	Number of Shares of each class Pre and Post split	As given in 3 above																											
7.	Number of shareholders who did not get any shares in consolidation and their pre consolidation shareholding.	Not Applicable																											

Annexure – IV

Brief Details of Amendment to the Articles of Association (“AOA”) of the Company

The Company proposes to amend the clauses and definitions of its Articles of Association by way of deletion and/or insertion and /or modification, subject to the approval of the shareholders. Upon receipt of such approval, the amended provisions shall be appropriately reflected in the Articles of Association of the Company as set out below:-

A. Deletion of following clauses

- ~~1. (j). “Equity Shares” means the equity shares of the Company having a face value of Rs.10/- (Rupee ten only) each.~~
- ~~74. The company may exercise the powers conferred under the Act with regard to having an official seal for use abroad, and such powers shall be vested in the Board.~~
- ~~94. If the seal of the Company is specifically required to be affixed on any instrument by applicable law, such seal of the company shall be affixed to such instrument only by the authority of a resolution of the Board or of a committee of the Board authorised by it in that behalf, and except in the presence of at least one director and of the secretary or such other person as the Board may appoint for the purpose; and those one director and the secretary or other person aforesaid shall sign every instrument to which the seal of the company is so affixed in their presence.~~

B. Modification in the following clauses by deleting strike through and adding the under-line wordings

30. (c) Every certificate ~~shall be under the seal and~~ shall specify the number and the distinctive number of shares to which it relates and the amount paid-up thereon and shall be signed by two Directors or by a Director and the Company Secretary, wherever the Company has appointed a Company Secretary.
89. (d) If any uncalled capital of the Company is included in or charged by any mortgage or other security the Directors may by instrument in writing, duly executed by the authorized signatory of the company ~~under the seal~~ authorize the person in whose favor such mortgage or security is executed or any other person in trusts for him to make calls on the members in respect of such uncalled capital and the provisions hereinbefore contained in regard to calls shall mutatis mutandis apply to calls made under such authority and such authority may be made exercisable either conditionally or under such authority and such authority may be made exercisable either conditionally or unconditionally and either presently or contingently and either to the exclusion of the Directors’ power or otherwise and shall be assignable if expressed so to be.
94. (i) Directors may from time to time appoint any person or persons to be the Attorney or Attorneys of the Company, under the Seal of the Company, for such purposes and with such Powers and authorities (limited to those vested in or exercisable by the Directors under these presents) and for such period and subject to such conditions as the Directors may think fit and revoke any such appointment.

XXXI. ~~MANAGER OR SECRETARY~~ – KEY MANAGERIAL PERSONNEL

95. Subject to the provisions of the Act, -

- (a) A chief executive officer, manager, chief financial officer, ~~manager~~ or secretary may be appointed by the Board for such terms, at such remuneration and upon such conditions as it may think fit; and any chief executive officer or manager, chief financial officer, secretary so appointed may be removed by means of a resolution of the Board;
- (b) A director may be appointed as chief executive officer, manager, chief financial officer, or ~~manager or~~ secretary.

C. Addition of following clause after clause XLI.

XLII. DIGITAL SIGNATURE

107. The Board of Directors of the Company, or any Committee thereof duly constituted by the Board, shall have the power to authorise any Director, Key Managerial Personnel, officer of the Company, or any member of such Committee, to execute, sign and authenticate, on behalf of the Company, any agreement, contract, deed, instrument or other document. Such execution may be carried out by affixing Digital Signature(s) or Electronic Signature(s), or by such other electronic mode as may be permitted under applicable laws, including the Information Technology Act, 2000, and the rules made thereunder, as amended from time to time. Any document or instrument so executed or authenticated pursuant to such authorisation shall be deemed to be duly executed on behalf of the Company.

Annexure – V

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment with change in designation of Dr. Ajay Thakker (DIN: - 00120887) from Chairman & Managing director to Chairman & Whole-time Director.
2.	Date of appointment	For a period of 5 years w.e.f. ensuing Annual General Meeting of the Company subject to approval of the members.
3.	Term of appointment	Appointment with change in designation of Dr. Ajay Thakker (DIN: - 00120887) from Chairman & Managing director to Chairman & Whole-time Director for a period of five years with effect from July 17, 2026, subject to approval of the members at the ensuing Annual General Meeting of the Company.
4.	Brief Profile	He holds a Bachelor of Medicine and a bachelor of surgery degree from Grant Medical College, University of Bombay and a diploma in medical radio diagnosis, from Topiwala National Medical College, University of Bombay. He has more than 40 years of experience in the field of medicine and healthcare. He is currently responsible for the overall management of the Company.
5.	Disclosure of relationships between Directors	Dr. Ajay Thakker is father of Dr. Ankit Thakker
6.	Information as required under Circular No. LIST/COMP/14/2018-19 and NSE/CML/2018/02 dated June 20, 2018 issued by the BSE and NSE, respectively	Dr. Ajay Thakker is not debarred from holding the office of Director by virtue of any SEBI Order or any other such authority

Annexure – VI

Sr. No.	Particulars	Remark
1.	Name of SMP	Mr. Aditya Gupta
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Based on the recommendation of the Nomination and Remuneration Committee, the Board at its meeting held on May 15, 2026 has approved appointment of Mr. Aditya Gupta as Senior Vice President – Corporate Affairs w.e.f May 15, 2026
3.	Date of appointment & Terms of Appointment	The date of appointment is w.e.f May 15, 2026 Term :- Not Applicable
4.	Brief Profile	Mr. Gupta is a seasoned healthcare industry professional with over 32 years of experience spanning medical devices, healthcare financing, corporate strategy, and sales leadership. He brings significant expertise in mergers & acquisitions, capital deployment, and building scalable healthcare platforms
5.	Disclosure of relationships between Directors	Not Applicable

Annexure – VII

Sr. No.	Particulars	Remark
1.	Name of SMP	Dr. Tushar Patil
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Based on the recommendation of the Nomination and Remuneration Committee, the Board at its meeting held on May 15, 2026, has approved appointment of Dr. Tushar Patil as Head Operations, Dombivli w.e.f. May 15, 2026
3.	Date of appointment & Terms of Appointment	The date of appointment as a Senior Managerial Personnel is w.e.f May 15, 2026 Term:- Not Applicable
4.	Brief Profile	Dr. Tushar Patil - Head Operation, Dombivli. He is a dedicated healthcare professional who has been associated with the Company for the past 16 years, with extensive experience in clinical and hospital operations. He previously served as the Unit Head of the Indore hospital, where he played a key role in strengthening operational efficiency and patient care delivery. Armed with a medical degree (MUHS, 2007) and a Master's in Health and Hospital Management (Dr. D.Y. Patil, 2010), he brings a strong foundation in patient care and strategic hospital administration. His career spans critical care, hospital commissioning, process optimization, and operational excellence. With expertise in quality assurance, hospital marketing, and management, he adopts a holistic approach to enhance patient outcomes and drive sustainable growth. Passionate about healthcare delivery, he is committed to elevating standards and ensuring service excellence across the organization.
5.	Disclosure of relationships between Directors	Not Applicable

Annexure – VIII

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Reappointment of M/s. Varma & Varma as Internal Auditor of the company.
2.	Date of appointment	May 15, 2026
3.	Term of appointment	Financial Year 2026-27
3.	Brief Profile	<p>M/s. Varma & Varma is a Chartered Accountant Firm registered with Institute of Chartered Accountants of India with ICAI. The firm was established in 1935 and is led by 33 partners. The audit firm has valid peer review certificate.</p> <p>The firm had empaneled with the Comptroller and Auditor General of India (CAG), the Reserve Bank of India (RBI), World Bank, Securities and Exchange Board of India (SEBI), Audit Bureau of Circulations (ABC) etc.</p> <p>The firm provides a range of services which include audit & assurance, tax representation & advisory services, incorporation & investment advisory services, Business consultancy and valuation services. The firm has significant experience in providing auditing, taxation & advisory services to Hospitals and Healthcare clients.</p>
4.	Disclosure of relationships between Directors	Not Applicable

Annexure – IX

Sr. No.	Particulars	Remark
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. V. J. Talati & Co as Cost Auditor of the company.
2.	Date of appointment	May 15, 2026
3.	Term of appointment	Financial Year 2026-27
3.	Brief Profile	M/s. V. J. Talati & Co., Cost Accountants, Mumbai (Firm Regd. No. R00213) has experience and expertise in Cost Audit over the years. The firm also provides Guidance for Maintenance of Cost Accounting Records as prescribed under the Companies (Cost Records and Audit) Rules, 2014 and certification as regards maintenance of Cost Records by the Company.
4.	Disclosure of relationships between Directors	Not Applicable